LONDON,June 19, 2025 — Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company’s dedication to long-term growth and partnership in the UK market.
The opening ceremony was attended by Hyoung-Ki Kim, CEO and Vice Chairman at Celltrion, Rosalind Campion, Director of the Office for Life Sciences and Mark Samuels, Chief Executive of Medicines UK, and the British Biosimilars Association. The event was marked with a ribbon cutting ceremony.
Strategically located in the heart of Uxbridge, the new office will serve as Celltrion UK’s central hub for UK operations. This move places Celltrion among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences, Daiichi Sankyo, that have established presence in Uxbridge – emerging as a leading hub for biotechnology and pharmaceutical innovation.
Speaking at the opening ceremony, Hyoung-Ki Kim, CEO and Vice Chairman of Celltrion, said, “The opening our new UK office marks a pivotal milestone in Celltrion UK history. This demonstrates our strong commitment to the UK, a strategic market for our growth. We are here for the long term and are invested in the future of biosimilars in the UK. We look forward to continued collaboration with local institutions and regulatory bodies to ensure sustainable access to high-quality biologic treatments.”
Rosalind Campion, Director of the Office for Life Sciences, added, “With the NHS prescribing already 80% generic by volume, the next frontier is Biosimilars. This is a pivotal time for the sector just before the introduction of the life sciences sector plan and the NHS 10 year plan.”
Mark Samuels, chief executive of Medicines UK, said, “Celltrion’s medicines are a critical part of the UK life sciences ecosystem, and I am delighted that the company is strengthening its investment in the UK with a new office, supporting British jobs and the supply of essential medicines for the NHS.”
The new headquarters also reflects continued growth for Celltrion UK, which has expanded its headcount by 20% over the past year. With an exciting pipeline of new products spanning across multiple therapeutic areas including allergy, endocrinology, ophthalmology and immunology anticipated over the coming years, the company expects further recruitment and investment in the coming years.
This move is the latest chapter in Celltrion’s long-term vision for the UK, demonstrating its dedication to being a trusted healthcare partner, a contributor to the UK economy, and a key player in the global biosimilars market.
Be the first to comment